| Biocept is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. Co.'s assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, show progression or be used for monitoring in order to identify specific resistance mechanisms. Co. has commercialized its Target-Selector assays for a number of solid tumor indications such as: breast cancer, non-small cell lung cancer, gastric cancer, prostate cancer, and ovarian cancer. We show 24 historical shares outstanding datapoints in our BIOC shares outstanding history coverage, used to compute BIOC market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BIOC market cap history over the course of time is important for investors
interested in comparing BIOC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BIOC versus a peer is one thing; comparing
BIOC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BIOC can fluctuate over the course of history.
With this page we aim to empower investors researching BIOC by allowing them to research the BIOC market cap history.